CTKB
Cytek Biosciences IncKey Statistics
About Cytek Biosciences Inc
Cytek Biosciences Inc (CTKB) is at the forefront of multi-parameter flow cytometry, offering advanced cell analysis solutions that drive innovation in the life sciences industry. The company's proprietary technologies play a critical role in pivotal research fields such as immunology, cancer diagnostics, and drug development, addressing the growing demand for high-precision cellular analysis. Cytek’s dedication to innovation, coupled with its robust customer support, positions it as a significant player within the biotechnology sector. With a comprehensive product range and a solid market footprint, Cytek is well-equipped to facilitate groundbreaking discoveries that can dramatically enhance healthcare outcomes.
Fundamentals
| Revenue (TTM) | $204.17M |
| Gross Profit (TTM) | $105.56M |
| EBITDA | $-36.30M |
| Operating Margin | -41.80% |
| Return on Equity | -20.90% |
| Return on Assets | -5.89% |
| Revenue/Share (TTM) | $1.60 |
| Book Value | $2.54 |
| Price-to-Book | 1.58 |
| Price-to-Sales (TTM) | 2.54 |
| EV/Revenue | 1.383 |
| EV/EBITDA | 222.69 |
| Quarterly Earnings Growth (YoY) | 73.50% |
| Quarterly Revenue Growth (YoY) | 6.50% |
| Shares Outstanding | $129.14M |
| Float | $96.62M |
| % Insiders | 8.43% |
| % Institutions | 67.59% |
Historical Volatility
Volatility is currently expanding